- Clearmind Drugs (NASDAQ:CMND) disclosed in an SEC submitting on Monday after the bell a prospectus to supply and promote frequent shares, subscription rights, warrants, and models to boost $50 million.
- The prospectus just isn’t a proposal to promote the securities and isn’t soliciting a proposal to purchase the securities.
- SEC submitting.
